How and where to order Dilantin (Phenytoin Sodium) 100 mg capsules online:

Shop:DRUGS FOR HEALTH - 10% discount coupon DFHDCC
Sellers:PHENYTOIN STORES
Prices:from $0.40 per pill
Forms:100 mg capsules or tablets
Quantity:20-2000 pills
Type:Phenytoin brand, Dilantin brand and generics
Payment:Visa, Mastercard, AmEx, Bitcoin
Delivery:Regular and express mail service
Shipping:Worldwide, including USA, UK, Europe, Canada, Australia


Indications and usage:

Dilantin (Phenytoin Sodium) is indicated for the treatment of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery.


Dosage and administration:

  • Adult starting dose in patients who have received no previous treatment is one 100 mg Dilantin extended capsule three times a day, with dose adjustments as necessary. For most adults, the satisfactory maintenance dose will be one capsule three to four times a day. An increase, up to two capsules three times a day may be made, if necessary.
  • Adult once-a-day dose: if seizure control is established with divided doses of three 100 mg Phenytoin extended capsules daily, once-a-day dosage with 300 mg Dilantin (Phenytoin Sodium) extended capsules may be considered.
  • Adult loading dose: reserved for patients in a clinic or hospital setting who require rapid steady-state serum levels and where intravenous administration is not desired. Refer to full prescribing information.
  • Pediatric starting dose is 5 mg/kg/day in two to three equally divided doses, with dosage adjustments as necessary, up to a maximum of 300 mg daily. Maintenance dosage is 4 to 8 mg/kg/day.
  • Serum blood level determinations may be necessary for optimal dosage adjustments-the clinically effective serum total concentration is 10 to 20 mcg/mL (unbound phenytoin concentration is 1 to 2 mcg/mL).


    Overdosage:

    The lethal dose of phenytoin in pediatric patients is not known. The lethal dose in adults is estimated to be 2 to 5 grams. The initial symptoms are nystagmus, ataxia, and dysarthria. Other signs are tremor, hyperreflexia, lethargy, slurred speech, blurred vision, nausea, and vomiting. The patient may become comatose and hypotensive. Bradycardia and cardiac arrest have been reported. Death is caused by respiratory and circulatory depression.

    There are marked variations among individuals with respect to phenytoin serum levels where toxicity may occur. Nystagmus, on lateral gaze, usually appears at 20 mcg/mL, ataxia at 30 mcg/mL; dysarthria and lethargy appear when the serum concentration is over 40 mcg/mL, but as high a concentration as 50 mcg/mL has been reported without evidence of toxicity. As much as 25 times the therapeutic dose has been taken to result in a serum concentration over 100 mcg/mL with complete recovery. Irreversible cerebellar dysfunction and atrophy have been reported.

    Treatment:

    Treatment is nonspecific since there is no known antidote.

    The adequacy of the respiratory and circulatory systems should be carefully observed and appropriate supportive measures employed. Hemodialysis can be considered since phenytoin is not completely bound to plasma proteins. Total exchange transfusion has been used in the treatment of severe intoxication in pediatric patients.

    In acute overdosage by Dilantin (Phenytoin Sodium) pills the possibility of other CNS depressants, including alcohol, should be borne in mind.


    Dosage forms and strengths:

    Dilantin (Phenytoin Sodium) is available as 30 mg and 100 mg extended-release capsules.


    Contraindications:

  • Hypersensitivity to Dilantin pills, its ingredients, or other hydantoins.
  • A history of prior acute hepatotoxicity attributable to phenytoin.
  • Coadministration with delavirdine.


    Warnings and precautions:

  • Withdrawal precipitated seizure: may precipitate status epilepticus. Dose reductions or discontinuation should be done gradually.
  • Suicidal behavior and ideation: monitor patients for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.
  • Serious dermatologic reactions: discontinue phenytoin at the first sign of a rash, unless the rash is clearly not drug-related. If signs or symptoms suggest SJS/TEN, use of this drug should not be resumed and alternative therapy should be considered.
  • Drug reaction with eosinophilia and systemic symptoms (DRESS) / multiorgan hypersensitivity: if signs or symptoms of hypersensitivity are present, evaluate the patient immediately. Discontinue if an alternative etiology cannot be established.
  • Cardiac effects: bradycardia and cardiac arrest have been reported.
  • Angioedema: discontinue immediately if symptoms of angioedema such as facial, perioral, or upper airway swelling occur.
  • Hepatic injury: cases of acute hepatotoxicity have been reported with Dilantin. If this occurs, immediately discontinue.
  • Hematopoietic complications: if occurs, follow-up observation is indicated and an alternative antiepileptic treatment should be used.


    Adverse reactions, side effects:

    The most common adverse reactions of this medication are nervous system reactions, including nystagmus, ataxia, slurred speech, decreased coordination, somnolence, and mental confusion.

    To report suspected side effects of Dilantin (Phenytoin Sodium) capsules contact Pfizer, Inc. pharmaceutical company or your local FDA.


    Drug interactions:

    Multiple drug interactions because of extensive plasma protein binding, saturable metabolism and potent induction of hepatic enzymes.


    Use in specific populations:

    Pregnancy

    Prenatal exposure to phenytoin may increase the risks for congenital malformations and other adverse developmental outcomes.

    Lactation

    Phenytoin is secreted in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Dilantin and any potential adverse effects on the breastfed infant from this medicine or from the underlying maternal condition.

    Pediatric use

    Initially, 5 mg/kg/day in two or three equally divided doses, with subsequent dosage individualized to a maximum of 300 mg daily. A recommended daily maintenance dosage is usually 4 to 8 mg/kg. Children over 6 years and adolescents may require the minimum adult dosage (300 mg/day).

    Geriatric use

    Phenytoin clearance tends to decrease with increasing age. Lower or less frequent dosing may be required.

    Renal and/or hepatic impairment or hypoalbuminemia

    Monitor unbound phenytoin concentrations in these patients.


    Information for patients:

    Administration information

    Advise patients taking phenytoin of the importance of adhering strictly to the prescribed dosage regimen, and of informing the physician of any clinical condition in which it is not possible to take the drug orally as prescribed, e.g., surgery, etc.

    Advise patients not to use capsules which are discolored.

    Withdrawal of antiepileptic drugs

    Advise patients not to discontinue use of Dilantin without consulting with their healthcare provider. This drug should normally be gradually withdrawn to reduce the potential for increased seizure frequency and status epilepticus.

    Suicidal ideation and behavior

    Counsel patients, their caregivers, and families that AEDs, including phenytoin sodium capsules, may increase the risk of suicidal thoughts and behavior and advise them of the need to be alert for the emergence or worsening of symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers.

    Serious dermatologic reactions

    Advise patients of the early signs and symptoms of severe cutaneous adverse reactions and to report any occurrence immediately to a physician.

    Potential Signs of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) and other systemic reactions

    Advise patients of the early toxic signs and symptoms of potential hematologic, dermatologic, hypersensitivity, or hepatic reactions. These symptoms may include, but are not limited to, fever, sore throat, rash, ulcers in the mouth, easy bruising, lymphadenopathy, facial swelling, and petechial or purpuric hemorrhage, and in the case of liver reactions, anorexia, nausea/vomiting, or jaundice. Advise the patient that, because these signs and symptoms may signal a serious reaction, that they must report any occurrence immediately to a physician. In addition, advise the patient that these signs and symptoms should be reported even if mild or when occurring after extended use.

    Cardiac effects

    Counsel patients that cases of bradycardia and cardiac arrest have been reported, both at recommended phenytoin doses and levels, and in association with phenytoin toxicity. Patients should report cardiac signs or symptoms to their healthcare provider.

    Angioedema

    Advise patients to discontinue Dilantin and seek immediate medical care if they develop signs or symptoms of angioedema, such as facial, perioral, or upper airway swelling.

    Effects of alcohol use and other drugs and over-the-counter drug interactions

    Caution patients against the use of other drugs or alcoholic beverages without first seeking their physician's advice.

    Inform patients that certain over-the-counter medications (e.g., antacids, cimetidine, and omeprazole), vitamins (e.g., folic acid), and herbal supplements (e.g., St. John's wort) can alter their phenytoin levels.

    Hyperglycemia

    Advise patients that this medication may cause an increase in blood glucose levels.

    Gingival hyperplasia

    Advise patients of the importance of good dental hygiene in order to minimize the development of gingival hyperplasia and its complications.

    Neurologic effects

    Counsel patients that phenytoin may cause dizziness, gait disturbance, decreased coordination and somnolence. Advise patients taking Dilantin not to drive, operate complex machinery, or engage in other hazardous activities until they have become accustomed to any such effects associated with this medicine.

    Use in pregnancy

    Inform pregnant women and women of childbearing potential that use of Dilantin (Phenytoin Sodium) pills during pregnancy can cause fetal harm, including an increased risk for cleft lip and/or cleft palate (oral clefts), cardiac defects, dysmorphic skull and facial features, nail and digit hypoplasia, growth abnormalities (including microcephaly), and cognitive deficits. When appropriate, counsel pregnant women and women of childbearing potential about alternative therapeutic options. Advise women of childbearing potential who are not planning a pregnancy to use effective contraception while using Dilantin, keeping in mind that there is a potential for decreased hormonal contraceptive efficacy.

    Instruct patients to notify their physician if they become pregnant or intend to become pregnant during therapy, and to notify their physician if they are breastfeeding or intend to breastfeed during therapy.

    Encourage patients to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry if they become pregnant. This registry is collecting information about the safety of antiepileptic drugs during pregnancy.


    Where to buy phenytoin online:

    To purchase Dilantin (Phenytoin Sodium) 100 mg capsules or tablets from reliable online pharmacies and drugstores at low prices please use resources described above on this webpage.


    Here is a list of popular medications containing phenytoin as a main active pharmaceutical ingredient; their trade names, forms, doses, companies - manufacturers, distributors, suppliers, researchers and developers:

    Trade name of the drug Pharmaceutical forms and doses Companies
    Dilantin
  • Capsules, Extended Release; Oral; Phenytoin Sodium 30 mg, 100 mg
  • Capsules, Extended Release; Oral; Phenytoin Sodium 30 mg
  • Injectable; Injection; Phenytoin Sodium 50 mg / ml
  • Suspension; Oral; Phenytoin Sodium 30 mg / 5 ml, 125 mg / 5 ml
  • Tablets, Chewable; Oral; Phenytoin Sodium 50 mg
  • Pfizer
  • Centre Specialites Pharmaceutiques
  • Neopharm, Israel
  • Parke-Davis
  • Primal Chemical
  • Warner Lambert
  • Zuellig Pharma
  • Epamin
  • Capsules; Oral; Phenytoin Sodium 100 mg
  • Injectable; Injection; Phenytoin Sodium 50 mg / ml
  • Suspension; Oral; Phenytoin 37.5 mg / 5 ml
  • Pfizer
  • Elea Laboratorio
  • Epanutin
  • Capsules; Oral; Phenytoin Sodium 25 mg, 50 mg, 100 mg, 300 mg
  • Injectable; Injection; Phenytoin Sodium 50 mg / ml
  • Suspension; Oral; Phenytoin Sodium 30 mg / 5 ml
  • Pfizer
  • Neopharm
  • Parke-Davis
  • Eptoin
  • Injectable; Injection; Phenytoin Sodium 50 mg / ml
  • Suspension; Oral; Phenytoin 30 mg / 5 ml
  • Tablets; Oral; Phenytoin Sodium 50 mg, 100 mg
  • Abbott